INOFEA developed a unique and patented platform technology called enzzen® to fit enzymes to in vivo and process conditions.
The use of enzymes by the biotech companies is strongly limited by the fact that enzyme structure is sensitive and fragile, like most proteins, and usually not fitted to in vivo and process conditions. Many expensive genetically engineered or biological enzymes show remarkable properties but need to be made more robust for deployment in the health industry.
Our technology platform is unlocking the full potential value of enzymes, providing a seamless level of enhanced properties, unlike any other existing technologies. Read more on enzymes (link to enzymes page).
enzzen® is capable of immobilizing any enzyme or cocktail of enzymes onto safe silica particles and protect them by growing a nano-structured shield on the outer surface of the particle. This formulation of enzymes thus prevents the process of enzyme denaturation and provides them with remarkable resistance to in vivo and process conditions, such as acidity, temperature, the presence of chaotropic agents, proteases, etc.
The result is an increased efficiency of enzzen®-formulated enzymes compared to commercially available enzymes, being more robust for deployment in the healthcare industry.
INOFEA is addressing the pharmaceutical companies and healthcare industries, for which the enzzen® applications are countless.